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A trial fibrillation (AF) is the most common arrhythmia in the United States, with ≈7 million Americans estimated to have AF by 2020.
1,2 A major cause of morbidity and mortality in AF is stroke. Pharmacological therapy for the prevention of stroke has undergone a renaissance with the advent of newer oral anticoagulants that are safe and effective alternatives to warfarin. However, the decision to initiate anticoagulation remains a subjective assessment of risks versus benefits. Although guided by well-validated risk scores for stroke and bleeding, [3] [4] [5] real-world decisions on anticoagulation continue to differ significantly from guideline recommendations, with many patients at high risk not receiving anticoagulation because of a perceived high risk of bleeding and many low-risk patients being anticoagulated as a result of a perceived low risk of bleeding, the so-called risk-treatment paradox. 6 This phenomenon, thought to account for the continued underuse of oral anticoagulation therapy, 7 has yet to be validated in a large outpatient-based practice. Therefore, the present study by Steinberg et al 8 in this issue of Circulation is a timely effort to better understand and address some of the reasons underlying this risk mismatch in thromboembolic assessment and anticoagulation therapy in a community outpatient-based group of patients with stable AF.
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The authors examined 10 094 AF patients enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) between June 2010 and August 2011. 9 This US prospective registry of incident and prevalent AF is formed by a multispecialty collaboration of healthcare providers, including primary care physicians, cardiologists, and electrophysiologists. It is the largest clinical registry of its kind in the United States, enrolling ≈10 000 patients from 200 US outpatient practices. The patients are followed up for at least 2 years to characterize real-world treatment and outcomes of patients with AF. The empirical stroke and bleeding risks were assessed by the CHADS 2 and Anticoagulation and Risk Factors in Atrial Fibrillation Study (ATRIA) scores, respectively, 5, 10 and were classified as low, intermediate, and high. They were then compared with physicians' similarly categorized assessments of stroke and bleeding risks. Multivariable linear regression models were used to determine factors that account for physician-empirical risk mismatch.
This study is elegantly designed, and the results are thought provoking. The results are startling for the nearly complete lack of agreement between empirical and physician-assigned risks for both stroke and bleeding. Disagreement between physician-assigned and empirical risks was seen in up to 80% of cases and was particularly marked for patients at high risk for stroke and bleeding, for whom physicians tended to underestimate risk in both instances. For example, only 16% of patients were assessed to be at high risk for stroke compared with 72% who were classified as high risk by the CHADS 2 score. In addition, only 7% of patients were rated as having a high risk of bleeding on anticoagulation therapy compared with 17% considered high risk by the ATRIA score.
In assessing stroke risk, physicians selectively emphasized specific risk factors such as prior stroke or transient ischemic attack and severe AF symptoms more than diabetes mellitus, hypertension, age, and congestive heart failure. Therefore, a patient is less likely to be assessed as being at high risk for stroke if he or she achieved a high CHADS 2 score by a combination of factors than if they had a prior history of stroke. On the contrary, there was less emphasis on anemia and significant renal disease in the assessment of bleeding risk relative to the ATRIA score. Overall, stroke risk had a more significant impact on anticoagulation decisions than bleeding risk. Thus, the results confirm those of prior studies indicating that physicians would accept a higher risk of bleeding for a lower risk of stroke. 7 When mismatch exists, physicians' subjective evaluation of risk, not objective tools, was the main driver of decision making.
Several important questions come to mind. First, how predictive are empirical risk scores of true event rates? Second, do these differences influence outcomes for anticoagulation? Third, is the discordance a reflection of a lack of complete understanding of the mechanisms for thromboembolism?
In the past 10 years, several different risk stratification schemes have been devised to predict stroke and bleeding risk. 5, [10] [11] [12] Among them, the CHADS 2 score has been most widely used for its simplicity and predictive capability. 5 Several improvements to CHADS 2 have been proposed that incorporate age, female sex, and renal function. [13] [14] [15] Yet, the predictive capability of objective risk scores for stroke has been shown to be modest at best 5, 16 because our understanding of the mechanisms of thromboembolism remains incomplete, in particular whether AF is merely an associated condition or is mechanistically linked to stroke. Prolonged AF previously was thought to predispose to atrial stasis and thrombus formation with subsequent embolism. Therefore, most embolic events were reported to occur if AF was >48 hours in duration, which was felt to be the minimum duration required for thrombus formation in the left atrial appendage before cardioversion. 17 However, recent data have cast doubt on this simple construct of AF burden, duration, and stroke. In a study of 2580 patients with pacemakers or defibrillators who were >65 years of age, although >50% of embolic strokes were associated with subclinical AF, only 15% of all embolic strokes were associated with subclinical AF >6 minutes within 1 month of the stroke. 18 On the other hand, in the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) study of asymptomatic AF detected in patients with a dual-chamber pacemaker, the duration of episodes was more important than the frequency of episodes in determining a patient's thromboembolic risk. Additionally, thrombosis in AF is located mostly, but not exclusively, in the left atrial appendage, 19 throwing another wrench into the equation. Therefore, the mechanisms of thromboembolism are more complex than previously thought and may be multifactorial. 20 The thromboembolism may be related to atrial stasis from an actual prolonged AF episode, with thrombus formation mostly in the left atrial appendage; or may be the result of chronic inflammatory 21 or structural and endothelial changes 22 throughout the entire atrium caused by multiple prior AF episodes; or may be merely an epiphenomenon associated with AF. With increasing use of long-term, continuous monitoring for AF, 18 there is also a shift to the idea of thromboembolic risk as a dynamic property composed of an interaction between AF burden and more traditional risk factors rather than based solely on a fixed set of risk factors per se as embodied by all contemporary risk stratification schemes. Thus, a long shadow is cast on the present and previous efforts that rely on more traditional risk factors. In light of this, it is not surprising that there is a mismatch between physicians' assigned and empirical models of risk.
Nevertheless, an interesting aspect of the study is the disconnect between treatment outcome and risk assessment. Although vastly underestimating stroke risk in the high CHADS 2 group, physicians chose to anticoagulate at least 70% of patients they consider to be at low risk for stroke, with an overall high rate of anticoagulation use of 76%. This is consistent with previous reports and suggests (1) that physicians view stroke as a feared outcome and would accept a higher rate of bleeding for a lower rate of stroke, (2) a general lack of familiarity with bleeding risk guidelines relative to those for stroke, and (3) that physicians recognize the limitations of that their own understanding of stroke risks and the current risk prediction models.
Several limitations diminish enthusiasm for this study. First, the study suffers from significant sampling bias because it is derived from a national registry, with >80% of patients treated by cardiologists and electrophysiologists. 23 The management of AF was quite heterogeneous in this group, with significant interspecialty differences in the use of rhythm control and anticoagulation between cardiologists and primary care physicians. 23 Thus, the results may not fully reflect real-world practices in the community, where the overall rate of anticoagulation use has been reported to be in the 50% to 60% range. 7, 24 A global registry aiming to enroll >50 000 patients in nearly 50 countries is underway and will go some way toward addressing this issue. 25 Second, the survey was conducted at a time when the newer oral anticoagulants just became available in the United States. Only ≈12% of patients in this series used dabigatran. 26 As dabigatran and direct anti-Xa agents become more widely used, 27 it remains unclear whether the choice of newer oral anticoagulants with their advantages of convenience and, in the case of apixaban, lower bleeding risk profile might affect rates of oral anticoagulant use, particularly in the high-risk bleeding group.
In summary, the present study by Steinberg et al 8 highlights the discordance between provider-assessed risk and empirical risk scores in AF, both of which remain far from precise. Thus, it underscores the importance of further research into the mechanisms of thromboembolism in AF.
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